BioMarin Pharmaceutical, Inc.

BioMarin Pharmaceutical Inc. is a leading biotechnology company specializing in the development and commercialization of innovative therapies for rare genetic diseases. Established in 1997 and headquartered in San Rafael, California, BioMarin is recognized for its deep expertise in genetics and molecular biology, with a primary focus on addressing unmet medical needs through targeted treatments. The company has introduced groundbreaking therapies for conditions such as achondroplasia, severe hemophilia A, phenylketonuria (PKU), and various lysosomal storage disorders, including mucopolysaccharidosis types I and VI. BioMarin operates globally, serving patients in over 70 countries and maintaining a significant presence in North America, Europe, Latin America, the Middle East, and Asia-Pacific. Its portfolio consists of eight approved medicines and a robust pipeline of clinical and preclinical candidates, aiming to advance the future of human health through transformative science. With dedicated manufacturing and research facilities, BioMarin's approach is anchored in targeting the root causes of genetic disorders, supporting its reputation as a pioneer in the biotechnology sector.